Print page |
Email page
| 
Download PDF
« Previous Release | Next Release »
Cambridge, MA - July 19, 2006 - Javelin Pharmaceuticals, Inc. (OTCBB:JVPH and anticipated on AMEX:JAV
7/20/06), announced that its CEO and Chief Medical Officer, Daniel B. Carr MD, will be interviewed live on
Market News First Radio (www.MN1.com) today, July 19, 2006 at 1:30pm E.D.T . The interview will be
conducted by MN1.com's online radio team, Dick Hunter and Mike the Analyst.
Dr. Carr, a leading authority on pain management, will provide listeners with an overview of Javelin
Pharmaceuticals, Inc. focused on its three late stage drug candidates for treatment of acute pain. The interview
will also discuss potential near-term catalysts for corporate growth.
To access the interview live, log onto www.MN1.com and click on the "listen now" button in the upper right
hand quadrant of your computer screen.
About Javelin
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop
new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the
pain management market. The Company has two drug candidates in Phase III clinical development and one in
late Phase II. One of these Phase III drug candidates, Dyloject™, is currently under review for Marketing
Authorization Application (MAA) approval in Europe. Previous clinical trials have demonstrated its safety and
rapid onset of action. For additional information about Javelin, please visit the company's website at
http://www.javelinpharmaceuticals.com or contact us directly.
About MN1.com
Market News First is an online market news provider offering sophisticated investors timely important
breaking news on the global capital markets that they can profit from. Market News First is the only online live
radio web site that brings investors real market news and features direct from companies ranging from the
OTC Bulletin Board to the NYSE.
Through daily live pressers we keep you current on the news of established companies while also bringing the
investing public many of the newest investment opportunities the capital markets have to offer. Market News
First's one-on-one interviews with the Presidents and CFOs of public companies, broadcasted on our website,
delivers answers to pressing questions investors would ask management themselves and provides insight into
the where a Company is today and where it may be headed in the near future.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of
today, and we disclaim any obligation to update this information. These statements are subject to
known and unknown risks and uncertainties that may cause actual future experience and results
to differ materially from the statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and development involve a high
degree of risk. Factors that might cause such a material difference include, among others,
uncertainties related to the ability to attract and retain partners for our technologies, the
identification of lead compounds, the successful preclinical development thereof, the completion
of clinical trials, the FDA review process and other governmental regulation, our ability to obtain
working capital, our ability to successfully develop and commercialize drug candidates, and
competition from other pharmaceutical companies.